3Batlle M, Perez Villa F, Garcia Pras E, et al. Down - regulation of matrix metalloproteinase - 9 ( MMP - 9) expression in the mycvardium of congestive heart failure patients [ J ]. Transplant Proc, 2007,39 ( 7 ) : 2344 - 2346.
4Fdkin LE, Birks EJ, George R, et al. A quantitative gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the mycocardium of patients with deteriorating heart failure requiring left ventricular assist device support[J ]. J Heart Lung Transplant, 2006,25(12) : 1413 - 1419.
5Ahmed SH, Clark LL, Pennington WR, et al. Matrix metallopro teinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease[J]. Circulation, 2006,113 (17) : 2089-2096.
6Mori S, Gibson G, McTiernan CF. Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model [J]. J Card Fail,2006,12(4): 314-325
7King MK, Coker ML, Jarnes AG, et al. Selective matrix metalloproteinase inhibition with developing heart failure: Effects on left ventricular function and structure[ J]. Circ Res,2003,92 : 177-185.
二级参考文献8
1Spinale FG. Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart : a potential therapeutic target. Cardiovasc Res 2000,46(2) :225-238.
2Spinals FG. Matrix metallproteinases:regulation and dysregulation in the falling heart. Circ Res,2002,90(5) :520-530.
3Siwik DA, Chang DL, Colucci WS. Interleukin - 1 beta and tumor necrosis factor - alpha decrease collagen syntheis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res,2000,86( 12 ) :1259-1265.
4Spinale FG, Coker ML, Heung LJ, et al. A matrixmetallo-proteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000,102(16) :1944-1949.
5King MK, Coker ML, Goldberg A, et al. Selective matrix metalloproteinase inhibition with developing heart failure:effects on left ventricular function and structure. Circ Res,2003,92 (2) :177-185.
6Dixon IM, Ju H, Reid WL, et al. Cardiac collagen remodeling in the cardlomyopathic Syrian hamster and the effect of losartan. J Mol Cell Cardiol, 1979,29 (7) : 1837 -1850.
7Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted over expression of tumor necrosis factor. Circulation2001,104(7 ) :826-831.
8McElmurray JH 3rd, Mukherjee R, New RB, et al. Angio-tension- converting enzyme and matrix metalloproteinase inhibition with developing heart failure:comparative effects of left ventricular function and geometry. J Pharmacol Exp Ther, 1999,29 (2) :799-811.
5OKADA Y,NARA K,KAWAMURA K.Localization of matrix metalloproteinase 9 (92 kDa gelatinase/type Ⅳ collagenase=gelatinase B) in osteoclasts:Implications for bone resorption[J].Lab Invest,1995,72:311-322.
6AIMES R T,QUIGLEY J P.Matrix metalloproteinase-2 is an interstitial collagenase:Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4 and 1/4 length fragments[J].J Biol Chem,1995,270:5872-5876.
7HAYASHIDA,TSUTSUI H,IKEUCHI M,et al.Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction[J].Am J Physiol Heart Circ Physiol,2003,285:H1229-1235.
8FRANCIS G,SPINALE F G.Matrix Metalloproteinases regulation and dysregulation in the failing heart[J].Cir Res,2002,90:520-530.
9GRAHAM H K,TRAFFORD A W.Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure[J].Am J Physiol Heart Circ Physiol,2007,292:1364-1372.
10ARENAS I A,XU Y,LOPEZ-JARAMILLO P,et al.Angiotensin Ⅱ-induced MMP-2 release from endothelial cells is mediated by TNF-α[J].Am J Physiol Cell Physiol,2004,286:C779-784.
